Skip to main content

Table 2 Studies evaluating the efficacy of IDegLira and IGlarLixi in patients with diabetes mellitus type 2 inadequately controlled with basal insulin

From: Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

Study DUAL-2 DUAL-5 LixiLan L
IDegLira Degludec IDegLira Glargine U100 IGlarLixi Glargine U100
Duration 26 weeks 26 weeks 30 weeks
Population 413 T2DM adults, A1c 8.7 ± 0.7%, basal insulin and metformin ± sulphonylureas or glinides; mean basal insulin dose at baseline 29 ± 8 557 T2DM, A1c 8.4/8.2 ± 0.9%, basal insulin (glargine) and metformin; mean basal insulin dose at baseline 31 ± 10 736 T2DM adults, A1c 8.1 ± 0.7%, basal insulin and metformin ± OAD; mean basal insulin dose at baseline 35 ± 9
Mean insulin dose (final) 45 45 41 66 47 47
ΔA1c − 1.9 − 0.9 − 1.8 − 1.1 − 1.1 − 0.6
Final A1c (week 30) 6.9 8.0 6.6 7.1 6.9 7.5
Δ body weight (kg) − 2.7 0.0 − 1.4 + 1.8 − 0.7 0.7
% A1c < 7% 60 23 72 47 34 13
A1c < 7% without weight gain (%) NA NA 50 20 34 13
A1c < 7% without hypoglycemia (%) NA NA 54 29 32 19
A1c < 7% without weight gain or hypoglycemia (%) 40 8 39 12 20 9
Hypoglycemia (%)a 24 25 28 49 40 42
  1. aDifferent definitions for hypoglycaemia were used in the two studies. For the DUAL 2 and 5 trials, confirmed hypoglycaemia was defined as the occurrence of episodes requiring assistance (severe), or episodes in which plasma glucose concentration (determined from self-monitored blood glucose) was less than 56 mg/dL, irrespective of symptoms. For the LixiLan-L trial, documented symptomatic hypoglycemia was defined as typical symptoms of hypoglycaemia accompanied by a measured plasma glucose concentration of #70 mg/dL